 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 904108
Online Users : 858
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15636
|
| Title: | Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters |
| Authors: | Liao, HC;Shen, KY;Yang, CH;Chiu, FF;Chiang, CY;Chai, KM;Huang, WC;Ho, HM;Chen, YH;Huang, MS;Liao, CL;Chen, HW;Huang, MH;Liu, SJ |
| Contributors: | National Institute of Infectious Diseases and Vaccinology |
| Abstract: | DNA vaccines for infectious diseases and cancer have been explored for years. To date, only one DNA vaccine (ZyCoV-D) has been authorized for emergency use in India. DNA vaccines are inexpensive and long-term thermostable, however, limited by the low efficiency of intracellular delivery. The recent success of mRNA/lipid nanoparticle (LNP) technology in the coronavirus disease 2019 (COVID-19) pandemic has opened a new application for nucleic acid-based vaccines. Here, we report that plasmid encoding a trimeric spike protein with LNP delivery (pTS/LNP), similar to those in Moderna's COVID-19 vaccine, induced more effective humoral responses than naked pTS or pTS delivered via electroporation. Compared with TSmRNA/LNP, pTS/LNP immunization induced a comparable level of neutralizing antibody titers and significant T helper 1-biased immunity in mice; it also prolonged the maintenance of higher antigen-specific IgG and neutralizing antibody titers in hamsters. Importantly, pTS/LNP immunization exhibits enhanced cross-neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and protects hamsters from the challenge of SARS-CoV-2 (Wuhan strain and the Omicron BA.1 variant). This study indicates that pDNA/LNPs as a promising platform could be a next-generation vaccine technology. |
| Date: | 2024-03-14 |
| Relation: | Molecular Therapy Methods and Clinical Development. 2024 Mar 14;32(1):Article number 101169. |
| Link to: | http://dx.doi.org/10.1016/j.omtm.2023.101169 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2329-0501&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001144544600001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85181739518 |
| Appears in Collections: | [劉士任] 期刊論文
[黃明熙] 期刊論文
[廖經倫] 期刊論文
[陳信偉] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP85181739518.pdf | | 3806Kb | Adobe PDF | 115 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
